So in terms of dosing of Develop that I use, um, when I use it in combination with Romopsin, I do start out with 75 mg um BID upfront um for patients who are young, who are tolerating the regimen well, uh, with Divela it at 75 mg. dose um and who are heading to transplant, which is potentially curative, they do continue the patients at 75 mg um up until they, they get their transplant. For other patients who may be older, who may have, who, who I think may not be able to tolerate um the regimen as well, or, or who we are using this regimen. Uh, as a palliative treatment, then I do decrease uh theve dose to 25 mg, um, to, to, to keep the, uh, to change or try to keep the disease under control. So the patients who, uh, I have treated with Develoci and Romosin um or Develoip um as monotherapy, um, they, they have various different Uh, PTCL subtypes and uh most of them have gotten chop therapy up front, um. I would say some have relapsed within a few weeks of finishing chop, whereas some relapse within a few months. Um, and in terms of overall response rates that I'm seeing, uh, I, I, I, I see clinical improvement in roughly about 70% of patients, uh, even if it's uh temporary. Um, what I'm seeing though is that Uh, what I'm observing in addition to that, is that, um, the, the duration of response is unfortunately, uh, still something that we need to work on. It's quite, it, you know, lasts usually only a few months. And so it is a race for me to um get the patients once they are in a complete remission, to get them, um, to bridge them to transplant right away.
Presenter
